Gilles Salles, University of Lyon
Patients in the PRIMA study who had achieved remissions for their follicular lymphoma by means of immunochemotherapy had only half the risk of recurrence if they also received maintenance therapy with rituximab for two years compared with those who did not. Gilles Salles from the University of Lyon discussed his findings with Peter Goodwin during the 2010 European Hematology Association annual congress in Barcelona.
Audio clip: Adobe Flash Player (version 9 or above) is required to play this audio clip. Download the latest version here. You also need to have JavaScript enabled in your browser.
2 Comments
Had F. L. since 9-1-2000 . 2 chemo, 1 with rituxin. 2 relapses. just treated with rituxin. No relapse in 4 years. cancer free as of 8-1-2010.
being treated by Dr. Stewart at MUSC
Charleston SC. Really been lucky.
John Peters
John Peters, i’m go happy for you! i have been diagnosed with FL and currently undergoing chemo (4th). I’ve been told i need to choose a follow up therapy. Either Rituxin every 3 months, or Zevalin.